HILTON HEAD, S.C., June 11, 2026. Ailethea Inc., a pioneering AI-native technology platform and operational company infrastructure, today announced the formal addition of Complyze LLC as a premier venture within its corporate portfolio. Under the terms of the integration, Complyze’s automated regulatory submission software is built on Ailethea’s proprietary multi-classifier artificial intelligence engine, TRIAD-AI. Ailethea operates an advanced business acceleration ecosystem that provides end-to-end infrastructure, capital, and operational suites, spanning finance, law, RevOps, and compliance validation, to companies delivering material benefit to People, Animals, and the Planet. The inclusion of Complyze aligns with Ailethea’s People pillar by serving the $1.2T+ global medical device and diagnostic market, which has traditionally operated under complex regulatory frameworks and extensive technical requirements.
Complyze addresses the industry workflow dynamic known as the “Regulatory Ping-Pong” effect. Medical device innovators typically navigate between three and eight iterative cycles of Additional Information requests from regulatory bodies during the submission process. By building Complyze’s compliance software on Ailethea’s TRIAD-AI engine, the platform brings predictive risk modeling and automated dossier generation to a process that has historically relied on manual curation.
This approach has already produced measurable results. In recent pilots run against three real Health Canada Class II to IV Medical Device License (MDL) dossiers, the TRIAD-AI-powered Complyze software achieved 100% first-pass acceptance. Every submission cleared on the initial pass, resulting in an estimated cost avoidance of $2.0 million per submission and reducing the projected time-to-market by 12 to 18 months.
“Most high-impact startups fail not because their core innovations are flawed, but because the commercialization journey is fundamentally broken,” said Ramon Dempers, Co-Founder and Chief Visionary Officer of Ailethea. “With Complyze, we are proving that building compliance software directly on our TRIAD-AI framework de-risks the path to market in even the most high-stakes regulated environments. We are not merely providing passive investment. We are supplying the intelligence layer and operating system that drives execution.”
“Most high-impact startups fail not because their core innovations are flawed, but because the commercialization journey is fundamentally broken,”
Beyond immediate medical device submission automation, including FDA 510(k), De Novo, and PMA pathways, the collaboration outlines a three-phase expansion roadmap powered by Ailethea’s continuous data flywheel. Phase 2 will introduce an automated, lightweight ISO 13485-aligned Quality Management System (QMS) module for small and midsize manufacturers. Phase 3 will launch an AI Audit Engine designed to continuously reconcile documentation against evolving global baselines, ensuring ongoing audit readiness.
“Utilizing Ailethea’s compounding dataset and specialized GxP-aligned software development lifecycles allows Complyze to leapfrog legacy software incumbents,” stated Jamie Moore, Chief Regulatory Officer of Complyze. “By building on TRIAD-AI, we deliver a durable data moat, audit-ready traceability under 21 CFR Part 11, and a 10-to-40x ROI for our customers. This partnership positions us to become the default regulatory operating system for modern health innovation.”
ABOUT COMPLYZE LLC
Complyze is a RegTech company transforming the architecture of life sciences regulatory compliance across North America. By pairing specialized human-in-the-loop validation with advanced automation, Complyze accelerates market clearance for medical breakthroughs, reducing operational delays to bring technologies to clinicians and patients faster.
